Skip to main content

IL-23

RT @MeralElRamahiMD: ⭐️Ustekinumab+MTX vs. UST+PBO in PsA?

➡️Additional MTX has no positive impact on UST effic

Meral K. El Ramahi, MD MeralElRamahiMD

6 months 2 weeks ago
⭐️Ustekinumab+MTX vs. UST+PBO in PsA? ➡️Additional MTX has no positive impact on UST efficacy for arthritis, enthesitis, dactylitis, skin, QoL, & function. *️⃣Thus, no evident to add or maintain ongoing MTX when starting UST Late-Breaking Poster#12. #ACR21 @RheumNow #ACRBest https://t.co/k96PPUtwct
RT @Janetbirdope: #Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #usteki

Janet Pope Janetbirdope

6 months 2 weeks ago
#Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #ustekinumab loses throne in #psoriasis and #psoriatic arthritis except maybe if concomitant inflammatory bowel disease post TNFi? Rapidly evolving PsA Rx. Abst#1773 #ACR21 @RheumNow https://t.co/Dkf2DFFsSK
RT @Janetbirdope: So are we in an era of #monotherapy with bDMARDs in #PsA? Ustekinumab & Secukinumab not different

Janet Pope Janetbirdope

6 months 2 weeks ago
So are we in an era of #monotherapy with bDMARDs in #PsA? Ustekinumab & Secukinumab not different w or without #MTX. Abst#L12 @RheumNow #ACR21 https://t.co/Zp5owTpLvm
RT @doctorRBC: Methotrexate did not improve Ustekinumab efficacy in tx of PsA
⭐️Addition of MTX did not improve dact

Robert B Chao, MD doctorRBC

6 months 2 weeks ago
Methotrexate did not improve Ustekinumab efficacy in tx of PsA ⭐️Addition of MTX did not improve dactylitis, enthesitis, skin, QoL or function #ACR21 #ACRBest @RheumNow Abs#L12https://t.co/6dxWPNskou https://t.co/BnzH8PfaMV
RT @doctorRBC: Phase 2 trial of tildrakizumab (IL-23i) for the treatment of PsA showed lower efficacy in pts with metabo

Robert B Chao, MD doctorRBC

6 months 2 weeks ago
Phase 2 trial of tildrakizumab (IL-23i) for the treatment of PsA showed lower efficacy in pts with metabolic syndrome compared to those without #ACR21 @RheumNow Abs#1819https://t.co/GYHbiH9NSW https://t.co/YGcZcITjzj
RT @doctorRBC: 2 year study shows low rates of radiographic progression in PsA pts on guselkumab
#ACR21 @RheumNow Abs#1

Robert B Chao, MD doctorRBC

6 months 2 weeks ago
2 year study shows low rates of radiographic progression in PsA pts on guselkumab #ACR21 @RheumNow Abs#1805https://t.co/dobg3cEXXG https://t.co/m1P24qPAhy
RT @DrPetryna: Abst1773 #ACR21 @rheumnow guselkumab outperforms ustekinumab in both msk & skin domains in bio naive

Olga Petryna DrPetryna

6 months 2 weeks ago
Abst1773 #ACR21 @rheumnow guselkumab outperforms ustekinumab in both msk & skin domains in bio naive & bio experienced alike- data from pivotal Phase III trials : at weeks 52 GUS better ACR20, PASI100 in both doses vs Stelara https://t.co/lfddaCJA5O
RT @RichardPAConway: No benefit to using MTX in combination with ustekinumab in PsA. No difference in efficacy for arthr

Richard Conway RichardPAConway

6 months 2 weeks ago
No benefit to using MTX in combination with ustekinumab in PsA. No difference in efficacy for arthritis, enthesitis, dactylitis, skin, QoL or function. Abstr#L12 #ACR21 @RheumNow https://t.co/iojKLqRb06
RT @RichardPAConway: Individual patient data analysis from RCTs (indirect comparison) of guselkumab vs ustekinumab in Ps

Richard Conway RichardPAConway

6 months 2 weeks ago
Individual patient data analysis from RCTs (indirect comparison) of guselkumab vs ustekinumab in PsA. Guselkumab appears superior for joint and skin. Abstr#1773 #ACR21 @RheumNow https://t.co/MTRjXyHoh6
×